Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Supracondylar Distal Femur Fractures and Abaloparatide
NCT04626141 · Daniel Horwitz · PHASE4 · withdrawn · last registry update 2024-05-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study withdrawn due to staffing/enrollment related challenges.” | – | Registry record, Daniel Horwitz |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTH1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-27Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLG2128 + Teriparatide Injection (NCT06898060)
- 2025-02-28Results posted on the registry: Ascendis Pharma Bone Diseases A/S, TransCon PTH + Placebo (NCT04701203)
- 2024-09-19Results posted on the registry: David Lunardini, Abaloparatide (NCT04760782)
- 2024-09-19Also stopped (terminated): David Lunardini, Abaloparatide (NCT04760782)
- 2023-12-04Phase 3 first posted: Pharmbio Korea Co., Ltd., PBK_L2201 + Placebo (NCT06154187)
- 2023-11-22Results posted on the registry: Radius Health, Inc., abaloparatide-sMTS (NCT04366726)
- 2023-08-02Results posted on the registry: Massachusetts General Hospital, Teriparatide + Denosumab (NCT04026256)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision